Genmab A/S (NASDAQ:GMAB) Receives Average Rating of “Buy” from Brokerages

Shares of Genmab A/S (NASDAQ:GMAB) have been given a consensus rating of “Buy” by the ten analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $23.67.

A number of brokerages have recently commented on GMAB. Zacks Investment Research lowered Genmab A/S from a “hold” rating to a “sell” rating in a report on Saturday, January 4th. ValuEngine upgraded Genmab A/S from a “sell” rating to a “hold” rating in a report on Tuesday, December 3rd. HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of Genmab A/S in a report on Wednesday, December 11th. Deutsche Bank lowered Genmab A/S from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, SunTrust Banks began coverage on Genmab A/S in a report on Monday. They issued a “buy” rating on the stock.

GMAB stock traded down $0.40 during midday trading on Thursday, hitting $22.68. 4,206 shares of the company’s stock were exchanged, compared to its average volume of 233,249. The stock’s fifty day moving average is $22.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.72 and a current ratio of 18.72. The company has a market cap of $2.89 billion and a P/E ratio of 6.03. Genmab A/S has a one year low of $14.48 and a one year high of $24.50.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $1.26 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $1.18. The company had revenue of $158.22 million for the quarter, compared to analyst estimates of $139.37 million. Genmab A/S had a return on equity of 16.26% and a net margin of 42.39%. On average, analysts predict that Genmab A/S will post 0.53 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in GMAB. Vestmark Advisory Solutions Inc. acquired a new stake in Genmab A/S in the third quarter valued at $268,000. Stifel Financial Corp purchased a new stake in Genmab A/S in the 3rd quarter valued at about $1,990,000. Envestnet Asset Management Inc. purchased a new stake in Genmab A/S in the 3rd quarter valued at about $2,698,000. Oppenheimer Asset Management Inc. purchased a new stake in Genmab A/S in the 3rd quarter valued at about $4,788,000. Finally, Simon Quick Advisors LLC purchased a new stake in Genmab A/S in the 4th quarter valued at about $30,000. 19.56% of the stock is currently owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

See Also: What is Cost of Goods Sold (COGS)?

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.